160 related articles for article (PubMed ID: 11591501)
1. Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.
Webber SE; Marakovits JT; Dragovich PS; Prins TJ; Zhou R; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Srinivasan B; Moran T; Ford CE; Brothers MA; Harr JE; Meador JW; Ferre RA; Worland ST
Bioorg Med Chem Lett; 2001 Oct; 11(20):2683-6. PubMed ID: 11591501
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids.
Dragovich PS; Webber SE; Prins TJ; Zhou R; Marakovits JT; Tikhe JG; Fuhrman SA; Patick AK; Matthews DA; Ford CE; Brown EL; Binford SL; Meador JW; Ferre RA; Worland ST
Bioorg Med Chem Lett; 1999 Aug; 9(15):2189-94. PubMed ID: 10465543
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Brown EL; Maldonado FC; Fuhrman SA; Zalman LS; Tuntland T; Lee CA; Patick AK; Matthews DA; Hendrickson TF; Kosa MB; Liu B; Batugo MR; Gleeson JP; Sakata SK; Chen L; Guzman MC; Meador JW; Ferre RA; Worland ST
J Med Chem; 2002 Apr; 45(8):1607-23. PubMed ID: 11931615
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Johnson TO; Hua Y; Luu HT; Sakata SK; Brown EL; Maldonado FC; Tuntland T; Lee CA; Fuhrman SA; Zalman LS; Patick AK; Matthews DA; Wu EY; Guo M; Borer BC; Nayyar NK; Moran T; Chen L; Rejto PA; Rose PW; Guzman MC; Dovalsantos EZ; Lee S; McGee K; Mohajeri M; Liese A; Tao J; Kosa MB; Liu B; Batugo MR; Gleeson JP; Wu ZP; Liu J; Meador JW; Ferre RA
J Med Chem; 2003 Oct; 46(21):4572-85. PubMed ID: 14521419
[TBL] [Abstract][Full Text] [Related]
5. Identification of quinone analogues as potential inhibitors of picornavirus 3C protease in vitro.
Jung E; Lee JY; Kim HJ; Ryu CK; Lee KI; Kim M; Lee CK; Go YY
Bioorg Med Chem Lett; 2018 Aug; 28(14):2533-2538. PubMed ID: 29866517
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.
Johnson TO; Hua Y; Luu HT; Brown EL; Chan F; Chu SS; Dragovich PS; Eastman BW; Ferre RA; Fuhrman SA; Hendrickson TF; Maldonado FC; Matthews DA; Meador JW; Patick AK; Reich SH; Skalitzky DJ; Worland ST; Yang M; Zalman LS
J Med Chem; 2002 May; 45(10):2016-23. PubMed ID: 11985469
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.
Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Reich SH; Marakovits JT; Prins TJ; Zhou R; Tikhe J; Littlefield ES; Bleckman TM; Wallace MB; Little TL; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; DeLisle DM; Worland ST
J Med Chem; 1998 Jul; 41(15):2819-34. PubMed ID: 9667971
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.
Namoto K; Sirockin F; Sellner H; Wiesmann C; Villard F; Moreau RJ; Valeur E; Paulding SC; Schleeger S; Schipp K; Loup J; Andrews L; Swale R; Robinson M; Farady CJ
Bioorg Med Chem Lett; 2018 Mar; 28(5):906-909. PubMed ID: 29433930
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.
Dragovich PS; Zhou R; Webber SE; Prins TJ; Kwok AK; Okano K; Fuhrman SA; Zalman LS; Maldonado FC; Brown EL; Meador JW; Patick AK; Ford CE; Brothers MA; Binford SL; Matthews DA; Ferre RA; Worland ST
Bioorg Med Chem Lett; 2000 Jan; 10(1):45-8. PubMed ID: 10636240
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.
Webber SE; Tikhe J; Worland ST; Fuhrman SA; Hendrickson TF; Matthews DA; Love RA; Patick AK; Meador JW; Ferre RA; Brown EL; DeLisle DM; Ford CE; Binford SL
J Med Chem; 1996 Dec; 39(26):5072-82. PubMed ID: 8978838
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Reich SH; Prins TJ; Marakovits JT; Littlefield ES; Zhou R; Tikhe J; Ford CE; Wallace MB; Meador JW; Ferre RA; Brown EL; Binford SL; Harr JE; DeLisle DM; Worland ST
J Med Chem; 1998 Jul; 41(15):2806-18. PubMed ID: 9667970
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication.
Kong JS; Venkatraman S; Furness K; Nimkar S; Shepherd TA; Wang QM; Aubé J; Hanzlik RP
J Med Chem; 1998 Jul; 41(14):2579-87. PubMed ID: 9651162
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Fuhrman SA; Patick AK; Matthews DA; Ford CE; Meador JW; Ferre RA; Worland ST
J Med Chem; 1999 Apr; 42(7):1203-12. PubMed ID: 10197964
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.
Dragovich PS; Prins TJ; Zhou R; Johnson TO; Brown EL; Maldonado FC; Fuhrman SA; Zalman LS; Patick AK; Matthews DA; Hou X; Meador JW; Ferre RA; Worland ST
Bioorg Med Chem Lett; 2002 Mar; 12(5):733-8. PubMed ID: 11858991
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
Dragovich PS; Prins TJ; Zhou R; Webber SE; Marakovits JT; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Ford CE; Burke BJ; Rejto PA; Hendrickson TF; Tuntland T; Brown EL; Meador JW; Ferre RA; Harr JE; Kosa MB; Worland ST
J Med Chem; 1999 Apr; 42(7):1213-24. PubMed ID: 10197965
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of tripeptidyl alpha-ketoamides as human rhinovirus 3C protease inhibitors.
Chen SH; Lamar J; Victor F; Snyder N; Johnson R; Heinz BA; Wakulchik M; Wang QM
Bioorg Med Chem Lett; 2003 Oct; 13(20):3531-6. PubMed ID: 14505664
[TBL] [Abstract][Full Text] [Related]
17. Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease.
Kawatkar SP; Gagnon M; Hoesch V; Tiong-Yip C; Johnson K; Ek M; Nilsson E; Lister T; Olsson L; Patel J; Yu Q
Bioorg Med Chem Lett; 2016 Jul; 26(14):3248-3252. PubMed ID: 27265257
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of 2,2-dimethyl-1,3-dioxolane derivatives as human rhinovirus 3C protease inhibitors.
Zhang Q; Cao R; Liu A; Lei S; Li Y; Yang J; Li S; Xiao J
Bioorg Med Chem Lett; 2017 Sep; 27(17):4061-4065. PubMed ID: 28778471
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.
Prior AM; Kim Y; Weerasekara S; Moroze M; Alliston KR; Uy RA; Groutas WC; Chang KO; Hua DH
Bioorg Med Chem Lett; 2013 Dec; 23(23):6317-20. PubMed ID: 24125888
[TBL] [Abstract][Full Text] [Related]
20. Non-covalent inhibitors of rhinovirus 3C protease.
Baxter A; Chambers M; Edfeldt F; Edman K; Freeman A; Johansson C; King S; Morley A; Petersen J; Rawlins P; Spadola L; Thong B; Van de Poël H; Williams N
Bioorg Med Chem Lett; 2011 Jan; 21(2):777-80. PubMed ID: 21183345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
